Panelists discuss how a patient named Kerstin was diagnosed with ADHD later in life during college when she struggled with organization and scheduling beyond her known dyslexia, leading to successful treatment with various stimulant medications including participation in clinical trials

Panelists discuss how stimulant and non-stimulant ADHD medications have different adverse effect profiles, with stimulants causing concerns like misuse potential, cardiovascular effects, tics, and growth suppression.

Debate over using SSRIs in pregnancy in recent FDA focus group raises questions, despite extensive research supporting SSRI use for maternal mental health.

There is no magical cure for PTSD... but in what areas can we improve treatment outcomes and real-world functioning for patients with PTSD?

Social media shapes mental health discourse, but misinformation and self-diagnosis risks arise as non-professionals dominate the conversation.

Effective psychodynamic strategies can help to engage difficult patients in psychotherapy, enhancing treatment outcomes and fostering meaningful therapeutic alliances.

Explore Canada's evolving psychiatric landscape, including innovative treatments and the ethical debate surrounding aid in dying for mental illness.

Discover 6 essential steps for psychiatrists to enhance the effectiveness of CBT and DBT in treating young patients.

Positive phase 2 results show that treatment with alixorexton led to statistically significant and dose-dependent improvements in sleep latency among patients with narcolepsy type 1.

BioXcel Therapeutics has submitted an pre-sNDA meeting package for Igalmi's outpatient use, aiming to enhance treatment options for agitation in bipolar disorders and schizophrenia.

Are Americans acting like zombies? How many of us are walking around in a traumatized daze, needing a creative political response?

Panelists discuss a woman aged 26 years with narcolepsy type 2 whose modafinil is ineffective and causes adverse effects, highlighting solriamfetol and oxybates as treatment options while emphasizing personalized care that integrates medication with lifestyle and behavioral strategies.

Panelists discuss the multifaceted barriers to medication adherence in narcolepsy, highlighting access issues, forgetfulness, mood disorders, and adverse effects, while emphasizing practical tools like habit-stacking, sleep logs, and routine reinforcement to support consistency and reframe treatment as a lifelong support rather than a temporary fix.

Gus Alva, MD, discusses the FDA committee vote on brexpiprazole for PTSD, what it means, and what's next.

A trio of practitioners react to the FDA advisory committee's 10-1 vote against recommending approval of brexpiprazole (Rexulti) adjunctive to sertraline for adults with PTSD.

Women with schizophrenia face increased breast cancer risks linked to long-term prolactin-raising antipsychotic use, highlighting the need for regular screenings and tailored treatment strategies.

The FDA advisory committee votes against brexpiprazole plus sertraline for PTSD, citing insufficient efficacy despite some positive trial results.

The strong emphasis on neuroscience in the 1990s and early 2000s is now giving way to a new psychiatric pluralism, one that increasingly views psychotherapy as real treatment and psychosocial factors as fundamental to understanding the causes and basic nature of psychopathology.

"Just like moons and like suns, With the certainty of tides, Just like hopes springing high, Still I'll rise..."

Seaport Therapeutics initiates a pivotal study for GlyphAllo, a potential breakthrough treatment for major depressive disorder, with or without anxious stress.

Social media use among older adults shows potential benefits for reducing loneliness and improving psychosocial well-being, though results vary across studies.

Proposed budget cuts threaten mental health services, risking patient care and community stability while exacerbating existing disparities in access to treatment.

FDA reviewers raise concerns over Rexulti's efficacy for PTSD, highlighting discordant study results ahead of the advisory committee meeting.

Rebecca Barbee, PA-C, CAQ-Psych, shares insights ahead of the the FDA meeting discussing brexpiprazole for PTSD.